1) and the manuscript that recently showed the prognostic value of cardiac troponin as a useful biomarker in acute aortic dissection (Ref 2). 8. The manuscript has to be edited prior to resubmission to assure that standard English grammar and usage are observed. 
GENERAL COMMENTS
In their prognostic study, Luo et al. stratified patients with type B aortic dissection (TBAD) according to levels of plasma NT-proBNP at presentation. They report worse outcomes in patients with higher levels of NT-proBNP. The aim is clinically meaningful and patient number adequate. Results are in line with preliminary findings in previous studies on small samples and on type A aortic dissection. However, definition of prognostic biomarkers is particularly important for TBAD, because protocols for optimal treatment and follow-up of these patients dramatically need amelioration. Key limits of the study are represented by: (1) inclusion of patients both in the acute and post-acute phase of TBAD, and (2) confounding effect of treatment (TEVAR vs medical treatment only) on outcome. I have the following specific comments:
Page 6, line 128. The authors need to provide the general test characteristics of the NT-proBNP assay used in their study. What are the validated cutoff values used for clinical use, e.g. in heart failure?
Page 7, line 137. Inclusion of patients independent of treatment approach is confounding, and I am not sure if statistical analyses accounted for this heavy covariate (TEVAR vs only medical treatment). Was TEVAR proposed to all patients with TBAD, even if uncomplicated? Please define the criteria used in your centers for patient selection for TEVAR. When was TEVAR scheduled?
The reduced rate of TEVAR in patients within the highest NTproBNP tertile (59% vs 72.73%) constitutes a relevant confounding factor. This category may include patients whose clinical conditions were substantially worse and in whom advanced treatment and support were considered as futile by treating physicians. In order to define NT-proBNP as a predictor of outcome, authors need to compare patients receiving similar treatments. The importance of TEVAR for patient outcome is shown in Tables 2 and 3 . The English language needs some minor check.
REVIEWER

Akira Sato
University of Tsukuba, Japan REVIEW RETURNED 25-Apr-2019
GENERAL COMMENTS
This study sought to investigate the relationships between NTproBNP levels and in-hospital and long-term adverse prognosis in patients with TBAD. A total of 657 consecutive patients with TBAD were enrolled in the study. The incident of in-hospital major adverse clinical events increased along with higher NT-proBNP (1.4% vs 11.5% vs 15.5%, p<0.001). NT-pro-BNP>210 pg/mL was independently associated with long-term death (adjusted HR=2.09, 95% CI, 1.22-3.57, p=0.007). They concluded that NT-proBNP was an independent predictor of adverse prognosis in patients with TBAD, which could be used as a potential risk-stratification tool.
My comments are related to the following points:
1) The strength of this paper is a large cohort for TBAD study. However, although the authors conclude that NT-proBNP was an independent predictor of adverse prognosis in patients with TBAD, there are undoubtedly unmeasured confounders that influence the adverse prognosis. Furthermore, they did not discuss why these data used in this study failed to prove mechanism underlying the adverse effects of NT-proBNP in aortic dissection. These features limit the interpretability of the authors' findings.
2) This study lacked data regarding the other prognostic biomarkers such as CRP and D-dimer in aortic dissection. This seems to me the interesting point of this study whether NTproBNP has incremental predictive value for the adverse prognosis over these biomarkers. However, unfortunately this point has not been adequately investigated.
Introduction
Line 104: The "And" at the start of the sentence is misplaced. The sentences should be joined or the word "And" dropped. Line 119: The abbreviation AD has not been defined. Line 122 typo: "Individuals who had no available admission …" Line 132: It would be helpful to know the percentage of records randomly checked. Line 145: The duration of follow up is not defined at this point in the article. There is no obvious stopping date for outcome events such as mortality to have occurred. The dates January 2010 to December 2015 were mentioned earlier, but these could be assumed to relate to the date of diagnosis of TBAD rather than the whole period of data considered. More clarity is needed here or earlier so that either the end date for follow up for outcome events or the length of follow up for outcome events is clearer. The reader's interpretation of the findings will depend on the definition of the outcomes, e.g. long-term mortality. This element would come under item 5 on the Strobe statement checklist. General comment: A weakness of using tertiles (or any other percentiles) to group data rather than fixed values, is that every dataset will have different values for these tertiles. However, the later analyses do not rely on tertiles and the messages from Table  1 are clearly explained. This is just an observation and no changes are needed. The statistical analyses are generally well described. In Table 1 , it is not appropriate to present a p-value for a statistical test to compare the measurements of NT-proBNP when groups have been defined by values of NT-proBNP. The modelling strategy is clearly defined. It is more common in recent years to choose a higher numerical value for the p-value cut off than 0.05 when selecting variables to go from the univariate analysis into the multivariable model. However, this would have affected only a couple of variables and I suspect would not materially affect the final conclusions. No change is required. Table 1 is more difficult to read because spaces have not been included between numbers and bracketed percentages and between medians and bracketed interquartile ranges. There is a similar difficulty for reading Tables 2 and 3 as there is no space after the comma within the confidence intervals. Discussion of limitations: There were several exclusion criteria which had the potential to introduced bias. Some discussion of these and the potential impact on results would be helpful. Response: Thank you for your suggestion. We added it.
VERSION 1 -AUTHOR RESPONSE
6. In the Methods section please define complicated vs uncomplicated type B dissection. How many pts in your population had complicated type B dissection? Indications for TEVAR?
Response: Thank you for your comment. Complicated TBAD was defined when presenting with recurrent or refractory pain; uncontrolled hypertension despite medical treatment; rapid aortic expansion; malperfusion of the viscera or limbs; signs of rupture (haemothorax, increasing periaortic and mediastinal haematoma) or hypotension/shock. 442 (67.3%) patients had complicated type B dissection. TEVAR was performed for patients with complicated TBAD according to current guidelines [Eur Heart J 2014; 35:2873 -2926 . Other factors such as false lumen diameter, location of the primary entry tear and retrograde component of the dissection into the aortic arch were also considered for elective TEVAR. However, patients who refused TEVAR because they did not accept the risk, or because of the cost of surgery, were treated with medication. Response: Thank you for your suggestion. We added it.
8. The manuscript has to be edited prior to resubmission to assure that standard English grammar and usage are observed. Response: Thank you for your suggestion. After revising according to the reviewer, this manuscript was edited by MedSci (www.medsciediting.com). And the certification of the editing was showed below. Response: Thank you for your comment. NT-proBNP was measured using a chemiluminescent immunoassay kit (Roche Diagnostics, Grenzach Wyhlen, Germany), with a normal range of 0-125 pg/mL. The cutoff used in heart failure was varied from different age: age<50 years (<450 pg/mL), age 50-75 years (<900 pg/mL) and age>75 years (<1800 pg/mL).
Response: Thank you for your comment. TEVAR was performed for patients with complicated TBAD.
Other factors such as false lumen diameter, location of the primary entry tear and retrograde component of the dissection into the aortic arch were also considered for elective TEVAR. However, patients who refused TEVAR because they did not accept the risk, or because of the cost of surgery, were treated with medication. The median day for TEVAR was 5 days after admission.
The reduced rate of TEVAR in patients within the highest NT-proBNP tertile (59% vs 72.73%) constitutes a relevant confounding factor. This category may include patients whose clinical conditions were substantially worse and in whom advanced treatment and support were considered as futile by treating physicians. In order to define NT-proBNP as a predictor of outcome, authors need to compare patients receiving similar treatments. The importance of TEVAR for patient outcome is shown in Tables 2 and 3 . Response: Thank you for your comment. NT-proBNP was measured at admission. The prognostic value of NT-proBNP in TBAD patients receiving different treatments was subgroup analyzed. NTproBNP remained as a predictor for long-term death in patients receiving TEVAR (AUC=0.682, 95%CI: 0.609-0.754, p<0.001) or conservative treatment (AUC=0.674, 95%CI: 0.583-0.764, p<0.001).
In addition, we included NT-proBNP and TEVAR into the same model. NT-proBNP remains a risk factor for long-term death (Table 3) .
Page 7, line 143-144. There is some confusion about the definition of acuity. The authors report that the chronic forms of TBAD (onset of symptoms to treatment > 90 days) were not analyzed. According to the classical definition, however, AD is chronic after 14 days. According to IRAD's classification (Booher AM, Am J Med 2013), AD is chronic after 30 days. Hence, I suggest that the authors focus on acute patients presenting within 14 days, and may extend data analysis to patients presenting within 30 days, but should discard chronic forms (>30 days). This heterogeneity introduces bias in data analysis. As shown in table 1, non-acute patients are not equally distributed among the three groups. Response: Thank you for your comment. The classical definition was according to the 2014 ESC guideline on the diagnosis and treatment of aortic diseases: acute AD (14 days), sub-acute (15-90 days), and chronic aortic dissection (>90days). [Eur Heart J 2014; 35:2873 -2926 .
Page 8. If available, please provide troponin levels. In table 1, it would be important to know the % of patients with depressed LVEF in each group. Response: Thank you for your suggestion. Troponin levels were not routinely measured in TBAD patients in our centres. Therefore, the troponin levels were not added. The rate of patients with depressed LVEF (<50%) was added in Table 1 .
The English language needs some minor check. Response: Thank you for your suggestion. After revising according to the reviewer, this manuscript was edited by MedSci (www.medsciediting.com). And the certification of the editing was showed below.
Reviewer: 3 Reviewer Name: Akira Sato Institution and Country: University of Tsukuba, Japan Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below This study sought to investigate the relationships between NT-proBNP levels and in-hospital and long-term adverse prognosis in patients with TBAD. A total of 657 consecutive patients with TBAD were enrolled in the study. The incident of in-hospital major adverse clinical events increased along with higher NT-proBNP (1.4% vs 11.5% vs 15.5%, p<0.001). NT-pro-BNP>210 pg/mL was independently associated with long-term death (adjusted HR=2.09, 95% CI, p=0.007) . They concluded that NT-proBNP was an independent predictor of adverse prognosis in patients with TBAD, which could be used as a potential risk-stratification tool. My comments are related to the following points:
Response: Thank you for your comment. This is a retrospective study. We found that elevated NTproBNP was associated with increased risk of in-hospital and long-term mortality in patients with TBAD. Although the mechanism underlying the association of NT-proBNP levels and prognosis in TBAD is unclear, some findings from previous published papers may contribute to this association. First, increased levels of NT-proBNP are a marker of renal dysfunction, due to decreased excretion from the kidney. In studies of aortic dissection, renal impairment on admission is associated with increased risk of postoperative renal failure and also with in-hospital and long-term mortality [Thorac Cardiovasc Surg 2016; 64:100-107; Am J Cardiol 2014; 113:1904 -1910 . In the present study, a linear correlation was observed between NT-proBNP and admission serum creatinine; however, this is cannot be the only contributing factor, because the effect of NT-proBNP on long-term mortality is not eliminated by including renal dysfunction into multivariate Cox analysis. Second, aortic dissection is defined as the separation between the layers of the aortic wall, resulting in luminal stenosis and decreased blood supply to organs. The latter, and consequent sharp pain, will further activate the sympathetic nervous and renin angiotensin systems [Am J Cardiol 2014; 113:1904 -1910 . All of these factors could cause increased blood pressure and strain on the left ventricular myocardium, leading to elevated secretion of NT-proBNP. Refractory hypertension is associated with adverse outcomes in acute aortic dissection [Circulation 2013; 127:2031 -2037 Circulation 2010; 122:1283 -1289 . In our analysis, we identified a significant positive association between admission SBP and increasing NTproBNP concentration. NT-proBNP levels may reflect this high pressure load, thus indicating poor prognosis. Third, a previous study showed that inflammation is an important factor in aortic dissection [Ageing Res Rev 2009; 8:31-35] . Changes in systemic inflammatory markers, such as interleukin-6, Creactive protein, tumor necrosis factor-a, and matrix metalloproteinase-9, are associated with acutephase reactions in aortic dissection, even where stenting has been performed [Clin Chim Acta 2012; 413:198-202] . Inflammatory cytokines may also have direct effects on BNP transcription and translation in cardiomyocytes [Eur J Prev Cardiol 2017; 24:676-684] . In this analysis, a trend towards a positive association between CRP and increasing NT-proBNP level was observed. Higher NT-proBNP was an indicator of inflammation, which contributes to poor prognosis. Finally, increased BNP also has direct adverse effects. Zhang et al. demonstrated that high BNP expression levels promoted cardiomyocyte apoptosis through activating the caspase-1/interleukin-1B signaling pathway [Mol Med Rep 2015; 12:6761-6767] . BNP can also enhance mild hypoxia-induced cardiomyocyte apoptosis by down-regulating the expression of Bcl2 mRNA [Biol Pharm Bull 2007; 30:1084 -1090 .
2) This study lacked data regarding the other prognostic biomarkers such as CRP and D-dimer in aortic dissection. This seems to me the interesting point of this study whether NT-proBNP has incremental predictive value for the adverse prognosis over these biomarkers. However, unfortunately this point has not been adequately investigated. Response: Thank you for your comment. CRP was not a risk factor for long-term mortality in our study (AUC=0.524, p=0.615, Figure A) . Instead, we compare the predictive value of NT-proBNP and Ddimer. The result showed that NT-proBNP had a similar power with D-dimer in predicting in-hospital death (AUC: 0.774 vs. 0.748, p>0.05, Figure 2 ). However, NT-proBNP had a higher predictive power for long-term death than D-dimer (AUC: 0.694 vs. 0.547 p<0.001, Figure B) . The abstract might need some minor changes. The main one relates to there being no intervention as it is a retrospective study, so this should be presented differently.
Objectives: "… unfavourable factor for poor outcomes"
